Alnylam Pharmaceuticals, Inc. (ALNY) vs Merck & Co., Inc. (MRK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ALNY | MRK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | LARGE | MEGA |
| Listing | Nasdaq GS | NYSE |
| Country | United States | United States |
| Theme | rare-disease | oncology |
| Price and returns | ||
| Last close | $227.66 | $140.61 |
| Return · 1 week | −2.41% | −2.10% |
| Return · 1 month | −10.85% | −5.43% |
| Return · 3 months | −21.06% | +6.67% |
| Return · year to date | −43.11% | +33.07% |
| Return · 1 year | −52.43% | +62.34% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −53.54% | −10.39% |
| 52-week high | $490.05 | $156.92 |
| 52-week low | $197.81 | $82.01 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $30.46B | $346.91B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $325.24M | $1.24B |
| Employees | 2,500 | 73,000 |
| Valuation | ||
| Price to earnings · trailing | 37.78× | 115.56× |
| Price to earnings · forward | 18.14× | 15.62× |
| Price to sales | 6.24× | 5.40× |
| Price to book | 22.13× | 8.57× |
| Enterprise value to EBITDA | 28.12× | 13.82× |
| Enterprise value to revenue | 6.17× | 6.00× |
| PEG ratio | 0.29 | 2.59 |
| Earnings per share · trailing | 5.93 | 1.26 |
| Profitability | ||
| Gross margin | 79.65% | 72.97% |
| Operating margin | 17.93% | −0.24% |
| Profit margin | 16.13% | 4.77% |
| Return on equity | 96.56% | 6.96% |
| Return on assets | 12.34% | 11.87% |
| Growth | ||
| Revenue growth | +66.90% | +5.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 220.62 | 128.41 |
| Current ratio | 3.06 | 1.32 |
| Dividend yield | 0.00% | 2.38% |
| Payout ratio | 0.00% | 266.67% |
| Trend and volatility | ||
| RSI · 14 | 45.27 | 42.46 |
| ADX · 14 | 11.31 | 16.51 |
| 50-day average | $239.03 | $146.74 |
| 200-day average | $289.02 | $126.01 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.37% | 3.41% |
The full ALNY analysis
Everything this table leaves out for Alnylam Pharmaceuticals, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ALNY argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ALNY analysisThe full MRK analysis
Everything this table leaves out for Merck & Co., Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MRK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MRK analysis